

Gmt

A2

12. (New) A method of treating or preventing metastasis in a mammal, including a human, comprising administering the alkylating anthracycline of formula Ia or Ib as claimed in Claim 1 and an antineoplastic topoisomerase II inhibitor.

13. (New) A method of treating a tumor in a mammal, including a human, by inhibiting angiogenesis comprising administering the alkylating anthracycline of formula Ia or Ib as claimed in Claim 1 and an antineoplastic topoisomerase II inhibitor.

REMARKS

Claims 1-6 and 10-13 are active in the present application. Claims 1-4 have been amended to remove multiple dependencies and for clarity. Claims 10-13 are new claims. Support for new claims is found in the original claims and in the specification, for example on page 2, line 20-26 and page 4, lines 9-19. No new matter is added. An action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/DJP/law

I:\atty\SUKOS\212136-PR.WPD

Marked-Up Copy

Serial No.:

Amendment Filed on:



08/22/01

IN THE CLAIMS

Claims 7-9 - (Cancelled).

Please amend the claims as follows.

--1. (Amended) [Products containing] A product comprising an alkylating anthracycline of formula Ia or Ib:



and an antineoplastic topoisomerase II inhibitor as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

2. [Products] The product according to claim 1 wherein the alkylating anthracycline is 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin.

3. [Products] The product according to claim 1 [or 2] wherein the topoisomerase II inhibitor is etoposide.

4. [Products] The product according to claim 1 [or 2] wherein the topoisomerase II inhibitor is doxorubicin.--

Claims 10-13 - (New).